Washington University School of Medicine in St. Louis has joined with Mallinckrodt Pharmaceuticals in a collaborative research partnership aimed at pursuing new therapies for patients with complex medical conditions, especially rare diseases that may have few or no treatment options. The global pharmaceutical company, which has maintained a presence in St. Louis since its founding